Recent

% | $
Quotes you view appear here for quick access.

Keryx Biopharmaceuticals Inc. Message Board

  • wkbcwashington wkbcwashington Feb 22, 2013 8:43 AM Flag

    Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference on FEB 27.

    Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference on FEB 27.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Zerenex has completed a U.S.-based Phase 3 clinical program for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA, and Keryx expects to submit an NDA with the FDA and a MAA with the EMA in the second quarter of 2013. Zerenex is also in Phase 2 development in the U.S. for the management of phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease. In addition, Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has filed its New Drug Application for marketing approval of ferric citrate in Japan for the treatment of hyperphosphatemia in patients with chronic kidney disease.

      Sentiment: Strong Buy

 
KERX
9.84-0.14(-1.40%)Jul 1 4:00 PMEDT